Sign In
Register
September 17, 20212:33 PM PDTLast Updated a month ago
Healthcare & Pharmaceuticals
Analysis: Torrid Moderna stock rally cools over booster shot doubts
By Lewis Krauskopf

4 minute read
1/2
A healthcare worker holds a vial of the Moderna COVID-19 Vaccine at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike Segar
NEW YORK, Sept 17 (Reuters) - Debate over the need for COVID-19 booster shots is clouding the outlook for Moderna Inc's (MRNA.O) high-flying shares after the U.S. biotechnology company's stock price soared as much as 360% this year, making it the best performer in the S&P 500.
A panel of expert outside advisers to the U.S. Food and Drug Administration on Friday voted to recommend COVID-19 vaccine booster shots for Americans 65 and older and those at high risk of severe illness, but rejected a request for broader approval.
The application for boosters for all Americans age 16 and older had been brought by Pfizer Inc (PFE.N) for the vaccine it developed with German partner BioNTech SE . Moderna, whose vaccine is based on a similar messenger RNA (mRNA) technology, applied earlier this month to allow use of a booster dose.
Moderna has benefited from being one of the dominant coronavirus vaccines, but its shares have pulled back 11% since hitting a closing high of $484.47 in early August. One factor in the rally stalling, analysts said, is a muddier outlook for additional booster COVID-19 shots, on top of the initial two-dose regimen.
“When (the stocks) ran up, I think it was expecting a booster shot to be given to everyone,” said Jeff Jonas, a portfolio manager at Gabelli Funds. "Now I think it’s maybe a little less certain that that extra demand is going to be there.”
The U.S. government had said it plans to start offering booster shots widely as soon as next week. But experts have questioned whether there is evidence to back such a plan.
This week, leading scientists, including two departing U.S. Food and Drug Administration officials, said in an influential medical journal that additional booster shots are not needed for the general population.
In a note earlier this week, SVB Leerink analysts estimated that the booster market is likely to add another $3 billion to $4 billion in U.S. revenue potential for existing vaccines.
Substantial booster revenue for the companies "are already contemplated in consensus estimates," the Leerink analysts said, "making the stock impact for Moderna in particular dependent on the breadth of the recommended population and boosting interval." read more
An already powerful rally in Moderna shares went into overdrive this summer, as index fund managers were forced to buy the stock after it was added to the S&P 500, and as concerns rose over a resurgence in COVID-19 cases due to spread of the virulent Delta variant of the virus.
The stock has been volatile since joining the index in mid July, with Moderna shares being either the biggest daily percentage gainer or loser in the S&P 500 in 10 trading days since the stock joined - a quarter of all the sessions over that time.
Reuters Graphics
Analysts overall appear to be cautious about the stock, even as the company is developing other products, including a vaccine that combines a booster dose against COVID-19 with its experimental flu shot.
The median price target for Moderna shares among 12 analysts is $391, according to Refinitiv, over 11% below Thursday's closing price of $440.65 read more
Using earnings estimates for the next 12 months, Moderna shares trade at a price-to-earnings ratio of 15.8, according to Refinitiv Datastream. That is more expensive than the 11.4 times P/E of S&P 500 biotech companies overall, but cheaper than the 17.7 of the S&P 500 healthcare sector (.SPXHC).
However, Moderna is also trading at about 15 times estimates of its sales in five years - a valuation level that large biotech stocks with one key product have peaked at historically, according to Hartaj Singh, a biotech analyst at Oppenheimer. Singh downgraded his rating on the stock to "neutral" in August.
"I don’t expect the stock to go down unless there is some unequivocal bad news that comes across," Singh said. "But I do think that a lot of the good news is already in the stock valuation."
Reporting by Lewis Krauskopf; Editing by Ira Iosebashvili and Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page

iPhone-maker Foxconn shows off its first EVs
Facebook plans to hire 10,000 in EU for 'metaverse'
Chips and ships: supply woes hit Philips outlook
EU has exported over 1 bln COVID-19 vaccines, von der...
Volvo eyes $23 bln value in share sale
U.S. homebuilders upbeat; Zillow hits pause
Amazon accused of possibly lying to Congress
Brexit, COVID brew storm for UK chicken farmers
Italy makes health pass mandatory for workers
After 75 years, it's the end for Alitalia
Read Next
India
India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say
10:20 PM PDT
Healthcare & Pharmaceuticals
Roche raises 2021 outlook as COVID-19 tests continue powering sales
10:21 PM PDT
Asia Pacific
New Zealand's daily COVID-19 cases fall, some classrooms to reopen
7:29 PM PDT
Asia Pacific
Tokyo aims to lift COVID-19 curbs on restaurants as cases fall - media
7:27 PM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · 10:20 PM PDT
India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say
India has delayed committing supplies of vaccine to the COVAX global sharing effort, two sources told Reuters on Tuesday, a day after one of its key backers, the WHO, said the agency could not "cut corners" to approve a domestically developed vaccine.
Healthcare & Pharmaceuticals
U.S. surgeons successfully test pig kidney transplant in human patient
5:38 PM PDT
Healthcare & Pharmaceuticals
U.S. Supreme Court justice rejects challenge to Maine COVID-19 vaccine mandate
4:49 PM PDT
Healthcare & Pharmaceuticals
EXCLUSIVE WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document
10:44 AM PDT
Healthcare & Pharmaceuticals
U.S. FDA to recommend Pfizer, Moderna boosters for people 40 and older -CNN
3:11 PM PDT
Latest
Home
Media
Videos
Pictures
Graphics
Browse
World
Business
Legal
Markets
Breakingviews
Technology
Investigations
Lifestyle
About Reuters
About Reuters
Careers
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Newsletters
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Westlaw
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
Onesource
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
Checkpoint
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Eikon
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
World-Check
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Cookies
Terms of Use
Privacy
Corrections
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved